Table 2.
The change of average ESAS score, and FAACT subscale and total scores from baseline
| At week 4 | At week 8 | At week 12 | P‐value (control vs. testosterone at week 12) | ||||
|---|---|---|---|---|---|---|---|
| Control group | Testosterone group | Control group | Testosterone group | Control group | Testosterone group | ||
| ESAS item a | |||||||
| Pain | −0.5 | −0.5 | −0.1 | −0.4 | −0.1 | −0.5 | n.s. |
| Fatigue | 0.7 | −0.1 | 0.3 | 0.3 | 0.5 | 0.2 | n.s. |
| Nausea | 0.0 | 0.3 | 0.6 | 0.0 | 0.4 | −0.1 | n.s. |
| Depression | 0.4 | −0.1 | 0.4 | 0.1 | 0.6 | 0.2 | n.s. |
| Anxiety | −0.2 | 0.9 | −0.1 | 0.3 | −0.3 | 0.0 | n.s. |
| Drowsiness | 0.0 | 0.4 | −0.2 | 0.1 | −0.7 | 0.0 | n.s. |
| Appetite loss | −0.1 | −0.3 | 0.1 | −0.4 | −0.7 | −0.4 | n.s. |
| Unhappiness | 0.1 | −0.5 | 0.0 | −0.9 | 0.0 | −1.4 | 0.007 |
| Dyspnoea | 0.2 | 0.5 | 0.2 | 0.5 | 0.2 | 0.3 | n.s. |
| Other problem | 0.6 | 0.6 | 0.4 | 0.4 | 0.4 | 0.3 | n.s. |
| Total | 0.5 | 0.1 | 2.4 | −0.8 | 0.3 | −1.6 | n.s. |
| FAACT subscale/total b | |||||||
| PWB | 0.0 | −0.7 | −0.1 | −0.3 | −0.5 | 0.1 | n.s. |
| SWB | −2.1 | −0.8 | −2.4 | −1.2 | −2.0 | −0.9 | n.s. |
| EWB | 0.4 | −0.8 | 1.3 | −0.5 | 0.5 | −0.8 | n.s. |
| FWB | −0.6 | −1.5 | −3.0 | −2.0 | −2.0 | −1.2 | n.s. |
| ACS | −1.1 | 0.1 | −0.4 | 0.8 | −0.2 | −0.3 | n.s. |
| FAACT TOI | −1.7 | −2.1 | −3.5 | −1.5 | −2.7 | −1.4 | n.s. |
| FACT‐G Total | −2.2 | −3.8 | −4.2 | −4.0 | −4.1 | −2.8 | n.s. |
| FAACT Total | −3.3 | −3.7 | −4.6 | −3.2 | −4.3 | −3.1 | n.s. |
ACS, anorexia cachexia subscale; EWB, emotional well‐being; FACT‐G, Functional Assessment of Cancer Therapy‐General; FWB, functional well‐being; n.s., not significant; PWB, physical well‐being; SWB, social/family well‐being; TOI, trial outcome index.
a
The higher the score, the worse the health‐related quality of life.
b
he higher the score, the better the health‐related quality of life.